Zepatier (grazoprevir/elbasvir) — Medica
Chronic Hepatitis C Virus (HCV) Genotype 1b
Initial criteria
- Patient is ≥ 12 years of age OR patient weighs ≥ 30 kg
- Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
- Approve for 12 weeks if patient is treatment‑naïve OR previously treated with pegylated interferon + ribavirin only
- OR approve for 12 weeks if patient previously treated with pegylated interferon + ribavirin + HCV protease inhibitor AND medication prescribed in combination with ribavirin
Reauthorization criteria
- Patient is currently receiving Zepatier for an approved indication and approval period sufficient to complete total recommended course
Approval duration
12 weeks